Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways. https://www.japantimes.co.jp/news/2025/12/12/world/science-health/alzheimers-trials-shift-approach/?utm_medium=Social&utm_source=mastodon #worldnews #sciencehealth #aging #dementia #alzheimer039s #pharmaceuticals #medicine #eisai #novonordisk